Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
AssigneeHealth Research, Inc.
InventorsTsann M. Chu, Lawrence D. Papsidero
Life of this patent
Estimating the term…
Abstract
Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are capable of shrinking solid tumors associated with human breast. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.
Claims7
A monoclonal antibody, produced by hybridoma cell line F36/22, which shrinks a solid tumor, said tumor-shrinking ability being demonstrated by a shrinkage of a human breast tumor xenograft in a nude mouse of about 15% to about 75% of tumor volume within about 3 days after administration of a tumor-shrinking effective amount of said antibody to a nude mouse bearing said human tumor xenograft.
Hybridoma cell line F36/22, ATCC number HB 8215, formed by fusing a P3x63Ag8.653 mouse myeloma cell with a mouse splenocyte obtained from a Balb/c mouse immunized with MCF-7 carcinoma cells, which produces a monoclonal antibody which shrinks a solid tumor, said tumor-shrinking ability being demonstrated by a shrinkage of a human breast tumor xenograft in a nude mouse of about 15% to about 75% of tumor volume within about 3 days after adminstration of a tumor-shrinking effective amount of said antibody to a nude mouse bearing said human tumor xenograft.
Dependencies are inferred from the claim text.